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Abstract 
Drug inaccessibility to vast areas of the tumor parenchyma is amongst the major hurdles for 
conventional therapies. Treatment efficacy rapidly decreases with distance from vessels and most 
of the tumor cells survive therapy. Also, between subsequent cycles of treatment, spared cancer 
cells replace those killed near the vessels, improving their access to nutrients, boosting their 
proliferation rate, and thus enabling tumor repopulation. Because of their property of "acting at a 
distance," radioisotopes are believed to overcome the physical barrier of vascular inaccessibility. 
Methods A novel molecular imaging tool called Cerenkov Luminescence Imaging (CLI) was 
employed for the detection of Cerenkov radiation emitted by beta particles, allowing in vivo 
tracking of beta-emitters. More precisely we investigated using a xenograft model of colon 
carcinoma the potential use of 32P-ATP as a novel theranostic radiopharmaceutical for tracing 
tumor lesions while simultaneously hampering their growth. 
Results Our analyses demonstrated that 32P-ATP injected into tumor-bearing mice reaches 
tumor lesions and persists for days and weeks within the tumor parenchyma. Also, the 
high-penetrating beta particles of 32P-ATP exert a "cross-fire" effect that induces massive cell 
death throughout the entire tumor parenchyma including core regions.  
Conclusion Our findings suggest 32P-ATP treatment as a potential approach to complement 
conventional therapies that fail to reach the tumor core and to prevent tumor repopulation. 
Key words: 32P-ATP radiopharmaceutical, Cerenkov luminescence imaging, magnetic resonance imaging, 
colorectal adenocarcinoma. 
Introduction 
Neoangiogenic programs in solid tumors 
generate convoluted and leaky blood vessels, which 
fail to uniformly perfuse the entire tumor parenchyma 
[1-4]. As new vessels stream from the peritumoral 
vascular network [1], vascularization is mainly 
restricted to the peripheral rim while the inner core is 
nearly avascular, hyper-dense, and subject to 
increased interstitial fluid pressure (IFP) [5]. The 
scarcity of vessels and the high IFP concur to form a 
physical barrier that limits drug penetration into the 
tumor core, reducing treatment efficacy [6]. Also, 
selective depletion of peripheral cells by radiotherapy 
or chemotherapy [7-10] shifts inner cells closer to 
vessels, improving their access to nutrients and 
oxygen [11], increasing their proliferation rate [9], and 









reducing efficacy during subsequent cycles of 
treatment [12, 13]. Hence, therapeutic approaches 
capable of killing tumor cells far from peripheral 
vasculature are of paramount medical importance. 
Owing to their property of "acting at a distance," 
radioisotopes are believed to overcome the physical 
barrier of vascular inaccessibility. Beta emitters have 
been used in the past to kill cancer cells and some of 
them, such as 131I and 90Yttrium, have successfully 
entered clinical practice [14, 15]. Cheng et al. [16-18] 
have demonstrated that 32P bound to ATP molecules 
(32P-ATP) is effective in damaging tumor cells and 
reducing tumor growth rate in nude mice. The 
maximum beta energy of electrons emitted by 
32P-ATP lies between that of 131Iodine and 90Yttrium 
with the particle range equal to 5 mm in tissues [19]. 
This property allows a “cross-fire effect” for cells 
located far away that cannot be physically reached 
through the bloodstream. Furthermore, the physical 
half-life of 32P is longer than 131Iodine and 90Yttrium, 
allowing the cell-damaging effect to persist for weeks 
after the first administration. This aspect is particular-
ly relevant for avascular regions of tumor parenchy-
ma where perfusion is delayed or inhibited [3].  
The recent development of a novel molecular 
imaging tool based on the detection of Cerenkov 
radiation (CR) by beta particles allows tracking of the 
bio-distribution of beta-emitters and their uptake 
within tumor parenchyma in vivo [20-22]. It has been 
shown that Cerenkov luminescence imaging (CLI) can 
be used to measure the bio-distribution of beta plus 
[23, 24] and beta minus emitters [25, 26]. This suggests 
that 32P-ATP can be considered as a novel theranostic 
radiopharmaceutical providing measurements of 
physiological proprieties of tumors (on the basis of its 
tumor-specific uptake) while inhibiting their growth 
and progression.  
To explore this hypothesis, we monitored the 
tumor-specific and whole-body distribution of 
32P-ATP in vivo by using CLI and determined the 
effects of treatment with 32P-ATP on tumor growth 
and microregional architecture of tumor parenchyma. 
We found that 32P-ATP perfused scarcely within 
tumor parenchyma, but once penetrated, persisted for 
weeks. Consequently, while slightly reducing tumor 
volume, 32P-ATP treatment induced damaging effects 
throughout the entire tumor parenchyma and 
especially within the tumor core, which is usually 
spared by conventional therapies. 
Results 
Single dose injection of 32P-ATP inhibits tumor 
growth over two weeks 
Sixteen nude mice were subcutaneously (s.c.) 
injected in the right rear flank with 2x106 HT-29 cells. 
At day 9 after injection, mice were randomized, and 8 
of them received intravenous (i.v.) injection of a single 
dose of 100 μCi of 32P-ATP in the lateral tail vein. 
Treatment induced a significant reduction of tumor 
growth rate compared to untreated animals, which 
persisted over 2 weeks after treatment (Figure 1A and 
B). At the endpoint of the experiment (30 days after 
cell injection), animals were sacrificed, and tumor 
growth was examined. Tumors from treated mice 
were 60% in weight compared to those from control 
mice (0.25±0.05 g and 0.41±0.14 g, respectively), 
although the difference was not statistically 
significant (p=0.23) (Figure 1C). 
The strong but transitory inhibition of tumor 
growth by a single dose injection of 32P-ATP is 
consistent with the half-life of 32P-ATP, which is equal 
to 14.3 days. In vivo monitoring of intratumor 
radioactivity by CLI confirmed that the beta particle 
emission within tumors shows a progressive decline 
after the initial i.v. injection but persists above the 
background level over 2 weeks (Figure 1D). 
The antitumor effect does not rely on the 
intrinsic properties of ATP 
It has been previously reported that extracellular 
ATP may provide per se a potent antitumor effect [27]. 
To further investigate this, two groups of mice were 
treated with Phosphate-Buffered Saline (PBS) or 
non-radioactive ATP using a dosage which is several 
orders of magnitude higher than that used in the 
32P-ATP treatment. In this setting, we did not find any 
appreciable difference in tumor growth rate between 
ATP treated and control tumors (Figure 1E-G). This 
demonstrates that, at least in our model, the 
antitumor effect of the 32P-ATP treatment is mainly 
due to the radioactivity and not because of the 
intrinsic properties of ATP per se. 
32P-ATP induces extensive cell death within 
the inner tumor parenchyma 
It is difficult to discern the microregional 
changes in the proliferation/death rate within the 
tumor parenchyma. Although the difference in tumor 
sizes between the 32P-ATP-treated and control mice at 
the end of the experiment was not statistically 
significant, histopathological analysis of tumor 
sections revealed that 32P-ATP caused a 2-fold 
increase in necrotic fraction compared to other 
treatments (Figure 2A). The extensive death areas in 
32P-ATP tumors exhibited signs of either fibrotic or 
hemorrhagic necrosis. Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay 
showed extensive DNA degradation in grossly 
necrotic areas. Also, in 32P-ATP tumors, but not in 





controls, TUNEL positive cells were still visible in 
close contiguity with necrotic areas, indicating an 
even larger spatial extension of death (Figure 2B). 
Necrosis was tumor-specific as it was absent in livers 
from the same animals (Figure 2C). Strikingly, while 
necrosis appeared fragmented in multiple small foci 
in control tumors, it appeared as a single patch or as 
few large necrotic foci often covering the entire tumor 
core in 32P-ATP-treated tumors (Figure 2D). However, 
outside necrotic areas, the density of Ki67-positive 
cells was unchanged in 32P-ATP-treated tumors 
compared to untreated tumors. This indicates that 
32P-ATP treatment induces massive cell death but 
does not directly affect cell proliferation rate in these 
tumors (Figure 3). 
Apoptosis lines the edge of necrotic areas in 
32P-ATP-treated tumors 
In general, extensive necrosis indicates that the 
death rate exceeds the ability of macrophages to clear 
dying cells, but does not provide information about 
timing and molecular pathways of cell death [28]. 
Molecular changes to tumor tissue following 
treatment precede changes in tumor morphology [29]. 
Activated caspase-3 is an early and specific marker of 
apoptotic cell death [30]. Spatial mapping of activated 
caspase-3 at the endpoint of the experiments might 
provide important clues about its dynamic 
 
Figure 1. Single dose injection of 100 µCi of 32P-ATP induces a temporary decline in tumor growth rate. Manual measurement by caliper (A); Magnetic Resonance 
Imaging (MRI) (B); At the endpoint of the experiment, tumor volume in 32P-ATP treated mice was reduced by 60% but did not reach statistical significance (C). In 
vivo monitoring 3 h to 14 days post injection) by CLI shows that after single dose injection, 32P-ATP emission decreases exponentially in the tumor as well as in 
other organs, but persists above the background value for over 2 weeks; (D). Treatment of HT29-tumor-bearing mice with non-radioactive ATP does not affect 
tumor growth rate, as measured either manually by caliper (E) or MRI (F), and tumor volume at the endpoint of the experiment. 





distribution. Interestingly, while in control tumors, 
activated caspase-3 was homogeneously distributed 
throughout necrotic foci, in 32P-ATP-treated tumors, it 
was restricted to the peripheral edge of the extensive 
necrotic areas (Figure 4A). This pattern of 
activated-caspase-3 immunostaining in 32P-ATP- 
treated tumors indicated a centrifugal temporal 
gradient of cell death, where dying cells were located 




Figure 2. Tumors from 32P-ATP-treated mice exhibited a significantly higher fraction of necrotic areas compared to those from either untreated, non-radioactive 
ATP-treated or PBS-treated mice (A). TUNEL assay on 32P-ATP-treated tumors revealed extensive contiguous DNA-fragmentation other than within grossly 
necrotic areas (B). Necrosis was restricted to tumors but was completely absent in other tissues such as liver (C). In 32P-ATP-treated tumors, necrosis extended over 
large regions often covering the entire tumor core while it appeared fragmented in multiple and small necrotic foci in control tumors (D). 






Figure 3. Tumors from 32P-ATP-treated mice displayed a higher fraction of necrotic (TUNEL positive) areas (A, black asterisks) and consequently a much smaller 
proliferating (Ki67-positive) area (A, red asterisks) compared to those from control mice (A). The density of Ki67-positive cells within the Ki67-positive area 
appeared similar between the two experimental groups (B and C). 
 
Necrotic regions exhibit a delayed but 
prolonged fluid perfusion 
It has been previously shown that the effect of 
conventional chemotherapy decreases with increasing 
distance from tumor blood vessels [7]. In contrast 
with this notion, we found that caspase-3 positive 
cells were located in distal areas from vessels (Figure 
5A).  
Contrast-enhanced magnetic resonance imaging 
(DCE-MRI) with gadolinium (Gd) as contrast agent 
allows monitoring of the dynamics of fluid perfusion 
within tumor parenchyma over time. Consistent with 
previous reports [3, 31], Gd perfusion is delayed in 
necrotic regions, but once penetrated, Gd is retained 
longer than it does in peripheral vascularized areas 
due to the inefficient wash-out. This may be because 
necrosis generated by the treatment might entrap 
32P-ATP inside tumor parenchyma thus allowing a 
sustained cross-fire effect on surrounding cells over 
time. As demonstrated by Cheng et al., 32P was 
actively incorporated into the phosphate-ribose 
backbone of DNA of rapidly growing cells, which 
could be one possible mechanism of entrapment. 
Repeated injection after 2 weeks enhances the 
inhibitory effect of 32P-ATP on tumor growth 
As shown above, the effect of a single-dose of 
32P-ATP on tumor growth is reduced 2 weeks after the 
injection, which is consistent with the physical 
half-life of 32P-ATP decay. We examined whether a 
second injection 7 days after the first one could 
prolong the effect of 32P-ATP and improve the efficacy 
of the treatment. As expected, the reduction in tumor 
growth rate that ensued after the first injection 
persisted over the entire duration of the experiment 
and at the endpoint (almost 20 days after cell 
injection), the tumor volumes of 32P-ATP-treated mice 
were significantly smaller than those from the 
controls (Figure 6A). There was no difference in the 
tumor growth rate between mice treated either with 
50 μCi or 100 μCi of 32P-ATP. CLI signal immediately 
after the second injection was much higher than that 
after the first injection, indicating a cumulative effect 
of 32P-ATP within the tumor parenchyma (Figure 6B).  






Figure 4. Apoptotic cells (caspase-3-cleaved -positive) were uniformly dispersed within necrotic foci in control tumors but were restricted to the edge of necrotic 
foci in 32P-ATP-treated tumors (A and B). Plots on the left of panel A display the histogram of color intensity as a function of distance along the yellow lines reported 
on the respective caspase-3-cleaved stained slide. Pink highlights on the plot indicate the tracts of the line passing through the grossly necrotic areas. Peaks appear to 
be uniformly spread along the line within the necrotic areas of control tumors and are mainly restricted to the edge of necrotic areas in the 32P-ATP treated tumors. 
 
Histopathologic analysis of 32P-ATP-treated 
tumors showed a significantly reduced number of 
necrotic foci that covered a considerably larger total 
fraction of tumor parenchyma (Figure 6C). 
Model of 32P-ATP antitumor effect 
Our data suggest that the antitumor action of 
32P-ATP proceeds through a dynamic process that is 
different from that of conventional chemotherapeutics 
(Figure 7). More precisely, in conventional therapies, 
drugs distribute mainly within the well-vascularized 
peripheral rim of the tumor and induce cell death 
locally. Depletion of peripheral cells improves 
vascularization of inner cells, which then proliferate 
faster and drive tumor repopulation between 
intermittent cycles of therapy. Sustained or multiple 
cycles of therapy allow a significant reduction of 
tumor volume, but inner cells become highly 
proliferative and more aggressive. The 32P-ATP 
treatment, on the other hand, reaches tumor core and 
its effect persists over days to weeks after a single 
dose injection. The proliferation of peripheral cells 
continues, but the extension of intratumor necrosis is 
large, and proliferating area at the peripheral rim is 
eroded. Although this results in limited reduction in 
tumor volume, the tumor core is destroyed and 
repopulation of inner cells is prevented. 






Figure 5. Co-immunostaining of 32P-ATP-treated tumor slices for markers of endothelial cells (Von Willebrand Factor, VWF, Green) and apoptotic cells (caspase 
3-cleaved, Red) revealed vessels and apoptosis in clearly distinct areas of tumor parenchyma (A). DCE-MRI with Gadolinium shows that necrotic regions (green 
circle) of 32P-ATP-treated tumors match with areas of tumor parenchyma where signal intensity appears later but persists longer (B). 
 
Discussion 
The limited accessibility of avascular tumor core 
to therapeutic drugs is amongst the major causes of 
therapy failure. Development of methods to avoid this 
limitation is an important challenge in medical 
oncology. Strategies that have been assessed to 
address this challenge in the last decades include: 
combination therapies aimed at improving tumor 
vascularization or reducing IFP [32, 33], development 
of drugs that selectively target hypoxic regions [34], 
and the use of devices that allow a controlled and 
continuous release of therapeutic drugs [35]. All these 
strategies, when successful, result in a significant 
increase of necrotic/apoptotic cell death throughout 
the entire tumor parenchyma, thus indicating the 
successful delivery of therapeutic drugs in regions 
that are normally inaccessible. Herein, we show that a 
single or double injection of 32P-ATP is sufficient to 
achieve the same result, inducing disruption of tumor 
structure throughout the entire tumor parenchyma 
and especially within the tumor core. 
The 32P-ATP-induced destruction of tumor 
parenchyma is due to two physical properties of 
32P-ATP, the spatial extension and the temporal duration 
of its beta-emission. With regard to the spatial 
extension, 32P-ATP acts at a distance since the range of 
electrons emitted by 32P-ATP has a length of 5 mm in 
tissues19. Therefore, the intratumor spatial 
distribution of 32P-ATP with its "cross-fire" effect is 
expected to extend 5 mm beyond the edge of the 
distribution area. This means that electrons emitted 
by 32P-ATP located at the peripheral rim would reach 
the core of tumors. As for the temporal duration, once 
32P-ATP enters the tumor, it emits beta particles for 
two weeks of its half-life and beyond unless it is 
cleared by the outward fluid flow. The lack of an 
efficient lymphatic drainage in the avascular tumor 
core limits 32P-ATP washout. This would enhance the 
efficacy of 32P-ATP therapy by allowing it to be 
entrapped, resulting in a persistent therapeutic action 
over days or weeks after the first injection. Consistent 
with this notion, necrosis exhibited a delayed but 





durable vascular perfusion by DCE-MRI [3]. Also, 
microscopic co-mapping of cleaved caspase-3 and the 
endothelial marker von Willebrand Factor showed 
accumulation of apoptotic cells distal from blood 
vessels, which is contrary to the reports showing a 
progressive decrease in the therapeutic effects of 
conventional drugs with increasing distance from 
vessels. 
Although the dynamic distribution of 32P-ATP 
within the tumor parenchyma and its uptake by 
tumor cells remain to be further investigated, our 
results provide, for the first time, evidence that 
32P-ATP can damage the architecture of tumor 
parenchyma to induce massive cell death that extends 
over the entire inner core. This suggests that 32P-ATP 
might be exploited alone, or in combination with 
other drugs, to overcome the physical barrier posed 
by the vascular inaccessibility of the tumor core. This 
can become a novel potential tool to remarkably 
improve the efficacy of treatments currently used in 
clinical settings.  
Due to the intrinsic tendency of 32P to 
concentrate in the bone, liver, and spleen, 32P-based 
drugs have been successfully used for decades in the 
treatment of myeloproliferative diseases [36-38]. Our 
results extend the potential use of 32P for the treatment 
of solid tumors and, more specifically, in combination 
with other therapies whose efficacy might be limited 
by the scarce intratumor accessibility. Nevertheless, 
the therapeutic use of 32P-based drugs is discouraged 
as it may induce side effects in long-term, such as an 
increased risk to develop leukemia [36-38].  
Our findings indicated clear benefits of 32P-ATP 
treatment in terms of massive cell death within the 
tumor core as well as a reduction in tumor volume. 
However, as for every new therapeutic approach, 
specific cost/benefit ratio needs to be determined in 
relation to a specific clinical context. By using CLI, we 
were also able to image and quantify the Cerenkov 
light emission of 32P-ATP in the whole animal and 
particularly in the tumor region. We can thus consider 
32P-ATP as a theranostic agent, at least for preclinical 
studies involving small animals.  
 
 
Figure 6. Injection of 2 subsequent doses of 32P-ATP at 1-week interval confirms and amplifies the anti-tumor effect reducing the tumor growth rate. Tumor volume 
in 32P-ATP-treated mice was significantly below the control group at the endpoint of experiments (A), as measured manually or by MRI. CLI displays an increase after 
the second injection indicating a cumulative effect (B). Necrosis covered a significantly larger total fractional area in 32P-ATCP treated tumors compared to controls 
but was concentrated in a reduced number of foci (C). 






Figure 7. A comparative diagram of the dynamic models of tumor progression in untreated tumors or those treated with conventional therapies or with 32P-ATP. 
Untreated tumors grow fast with a minimal frequency of spontaneous apoptotic cell death within the tumor core; tumor treated with conventional therapies exhibit 
massive cell death along the peripheral rim where efficient vessels allow drug penetration. Tumor volume does not increase during the treatment, but inner cells 
proliferate faster and drive tumor repopulation. In 32P-ATP-treated tumors, the tumor volume is less reduced than it is in conventional therapies, but the tumor core 
is massively destroyed and tumor repopulation is prevented.  
 
Materials and methods 
Animals 
All animal experiments were approved by 
Verona University Ethical Committee and authorized 
by Ministerial Decree (Aut. n.29/2014-B). Animal 
experiments were in accordance with the Amsterdam 
Protocol on animal protection and welfare and 
conducted according to the guidelines of Federation 
of European Laboratory Animal Science Associations 
(FELASA). 
Treatment 
A pilot experiment was performed aimed at 
comparing the anti-tumor effect of 32P-ATP with 
non-radiolabeled ATP. 24 nu/nu mice, inoculated 
subcutaneously with 2x106 HT-29 cancer cells, were 
subdivided into the following groups and received: 1) 
32P-ATP-treated (n = 8): a single intra venous (i.v.) 
injection of 32P-ATP (3.7 MBq) at day 9 after HT-29 cell 
inoculation; 2) ATP-treated (n = 8): i.p injection of 1 ml 
of 25 mM ATP (pH 6.2) in PBS solution for 10 days 
starting from day 9 after HT-29 cell injection; 3) 
PBS-treated (n = 4): daily i.p. injection of 1 ml of PBS 
for 10 days; 4) non-treated (n = 4).  
32P-ATP (Perkin Elmer) 3000 Ci/mmol was 
injected into the tail vein when the highest diameter of 
their tumors reached the size of 8–10 mm.  
Once the beneficial effect of 32P-ATP treatment 
was demonstrated in this cancer model, we designed 
a new experiment aimed at assessing the effect of a 
double injection of 32P-ATP. 24 nu/nu mice were 
inoculated subcutaneously with 2x106 HT-29 cancer 
cells and subsequently randomized into 3 groups: 1) 
32P-ATP – 100 µCi – treated (n = 9): received 2 
injections of 32P-ATP (100 µCi) at day 7 and 14; 2) 
32P-ATP – 50 µCi – treated (n = 9): received 2 injections 
of 32P-ATP (50 µCi) at day 7 and 14; 3) non-treated (n = 
8). 
Tumor growth was measured by the width (W) 
and length (L) of the tumor twice a week using 
calipers. Tumor volume was calculated using the 
formula (W2xL)/2.  
Magnetic resonance imaging  
All animals underwent MRI examination the day 
before injection of 32P-ATP and the first and second 





week post injection. Mice were anesthetized by 
inhalation of a mixture of air and O2 containing 0.5-1% 
isoflurane and were placed in a prone position inside 
a 3.5 cm i.d. transmitter-receiver birdcage coil. Images 
were acquired using a Biospec tomograph (Bruker, 
Karlsruhe, Germany) equipped with a 4.7-T, 33 cm 
bore horizontal magnet (Oxford Ltd., Oxford, UK). 
Turbo RARE-3D images were acquired for tumor 
localization and volume measurements using the 
following parameters: TR = 1200 ms, TE = 47 ms, slice 
thickness = 25 mm, field of view (FoV) = 5 cm × 2.5 cm 
× 2.5 cm, matrix size = 256 × 128 × 32.  
DCE-MRI was performed with Gd-DTPA 
(Magnevist®; molecular weight 0.57 kDa) as a 
contrast agent. A dynamic series of transversal RARE 
t1-weighted images were acquired with the following 
parameters: repetition time/echo time 300/10.7 ms, 
matrix size 256 × 128, FoV = 6 cm × 3 cm, the number 
of averages = 8. The acquisition time for a single 
image was 57 s; dynamic scans of 30 images were 
acquired at 5 s intervals (total acquisition time 
approximately 31 min).  
The contrast agent at 300 μmol/kg dosage was 
injected in a bolus during the interval between the 
fifth and the sixth scans. A phantom containing 1 mM 
Gd-DTPA in saline was inserted in the FoV and used 
as an external reference standard. 
Cerenkov luminescence imaging acquisitions 
All the CLI acquisitions were performed using 
the IVIS Spectrum optical imager (Perkin Elmer, 
Massachusetts, USA), equipped by a -90 ˚C cooled 
camera sensor back-thinned, back-illuminated grade 1 
CCD 2.7 cm × 2.7 cm, 2048 pixel × 2048 pixel. During 
image acquisition, mice were kept under gaseous 
anesthesia (2% of isoflurane and 1 L/min of oxygen).  
The images were acquired in bioluminescence 
modality with FoV = 13 cm and with the following 
parameters: exposure time = 300 s, f = 1, binning = 8. 
Dark measurements were obtained before image 
acquisition and subtracted from the luminescence 
images. Images were acquired and analyzed with 
Living Image 4.4 (Perkin Elmer, Massachusetts, USA). 
Measurements of the total flux (photons/s) were done 
on regions of interest (ROIs) drawn on the optical 
images corresponding to the entire body or the tumor 
region.  
Post-mortem analyses 
Quantification of the necrotic fraction 
At the endpoint of the experiment, tumors were 
dissected, fixed overnight in 4% paraformaldehyde, 
and embedded in paraffin for subsequent 
histopathological analysis. Necrotic areas were 
quantified on 5 µm thick sections stained with 
Hematoxylin & Eosin. Multiple images were acquired 
covering the whole section and the percentage of 
necrotic area (i.e. necrotic area/ total area ratio) was 
calculated on each image using ImageJ software. 
Immunohistochemistry 
Proliferating cells were identified in tumor 
sections by immunohistochemical staining with an 
antibody specific for Ki67 antigen (Abcam #ab15580). 
Apoptotic cells were identified and quantified on 
tumor sections by immunohistochemical staining 
with an antibody specific for caspase-3-cleaved 
(Asp175, Cell Signaling #9661S). Ki67 and 
caspase-3-cleaved-positive cells were mapped and 
quantified. Pictures were obtained by the automated 
acquisition and assembling of multiple images 
covering the whole sections. 
Death-associated DNA fragmentation was 
assessed by TUNEL assay (Roche Applied Sciences 
#11684817910) on tumor sections according to the 
manufacturer’s protocol. 
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